Table 1.
Statistical data of the groups with and without preoperative transarterial chemoembolization
| Demographics | TACE (n = 88) | No TACE (n = 116) | t | P value |
| Age (yr) | 49.34 ± 8.06 | 50.90 ± 7.70 | -1.401 | 0.163 |
| Child | 7.33 ± 2.69 | 7.23 ± 2.46 | 0.267 | 0.789 |
| MELD | 8.36 ± 7.16 | 8.07 ± 5.74 | 0.324 | 0.747 |
| IBL (mL) | 2944.32 ± 4008.34 | 2528.79 ± 2681.56 | 0.886 | 0.377 |
| IOA (mL) | 1910.34 ± 2902.87 | 1539.53 ± 2532.91 | 0.972 | 0.332 |
| AFP (ng/L) | 3439.08 ± 6623.56 | 1922.59 ± 5180.01 | 1.835 | 0.068 |
| Disease-free survival time (mo) | 20.77 ± 17.52 | 32.79 ± 22.63 | -4.131 | < 0.001a |
| Survival time with tumor (mo) | 1.88 ± 3.10 | 0.68 ± 2.10 | 3.278 | 0.001a |
a
P < 0.05, TACE vs no TACE. TACE: Transarterial chemoembolization; Child: Child-Turcotte-Pugh classification; MELD: Model for end-stage liver disease; AFP: α-fetoprotein; IBL: Intraoperative blood loss; IOA: Intraoperative autotransfusion.